World Immunotherapy Congress - Agenda Day 2

 

World Immunotherapy Congress 2018, Day 2

08:00 Registration Opens

08:50 Conference doors open

Combination therapies

Panel discussion
09:10

Keynote panel: Combination therapy strategies

  • Combination therapies – what are the next steps?
  • Toxicity and efficacy
  • Latest research and news
Matthew Robinson, Associate Director, Oncology Research, MedImmune Cambridge
Lamine Mbow, Senior Vice President & Head, Glenmark Pharmaceuticals SA

10:10 Networking refreshment break

Oncology – immunotherapy for solid tumours

Manufacture, logistics and supply chain

Chaired by Jonathan Back, Deputy Director, Project Team Lead, Drug Discovery, Glenmark Pharmaceuticals

Chaired by TBC

Immunotherapy - Immunotherapy for solid tumours
11:25

Microenvironmental links between adipose tissue and cancer

  • Excess adiposity in obesity has been associated with increases risk of cancer development as well as negative prognosis in several cancer types
  • Preclinical models of cancer and obesity will be presented
  • Contribution of cellular constituents of the adipose tissue to tumour development will be discussed
Immunotherapy - Manufacture, logistics and supply chain
11:25

Closed systems for CAR T-cell production

  • Closed non-magnetic selection technology (automated T-CATCH)
  • Soluble reversible activation technology (Expamer)
  • Short production process (Nex-T)
Immunotherapy - Immunotherapy for solid tumours
11:45

T-SIGn viruses: systemic delivery of localised combination immuno-gene therapy within the tumour microenvironment

  • T-SIGn platform: transgene-bearing genetically modified variants of enadenotucirev, an oncolytic chimeric group B adenovirus with clinical data demonstrating virus delivery to tumours following systemic dosing
  • Up to 4 different transgenes have been encoded in a single virus, enabling the design of candidates expressing combinations of biological agents for targeted immunotherapy
  • Local production of therapeutic combinations by tumour cells infected with the T-SIGn virus enables high local production for increased activity while minimizing systemic exposure for improved safety
Immunotherapy - Manufacture, logistics and supply chain
11:45

Cell therapy supply chain management, logistics and scale out

  • Shipper suitability, features and options
  • Maintaining chain of custody for starting material and product
  • Logistics reliability and options
  • Supply chain sustainability and scale-out
Immunotherapy - Immunotherapy for solid tumours
12:05

T cell redirecting antibodies based on Glenmark’s BEAT® platform

  • Presentation of GBR 1302 a CD3xHER2 T cell redirecting BEAT antibody currently in clinical development in metastatic breast and gastric cancers
  • Preclinical data highlighting the mechanism of action, and potency, in relation with standard of care
  • Translational data on primary cancer samples in relation with checkpoint combination and immune contexture
Immunotherapy - Manufacture, logistics and supply chain
12:05

Development of endogenous and engineered TCR-T cell therapies for solid cancers

  • Immatics has a proprietary tumor antigen targets discovery platform, XPRESIDENT® which identifies tumor targets and screen TCRs against off-target toxicities
  • Endogenous and engineered TCRs against these tumor targets are used in Immatics’ Adoptive Cellular Therapy programs
  • IMA101 is a multi-product endogenous T cells against a warehouse of targets against various solid cancers currently in phase 1 clinical trial
  • IMA201, 202, and 203 are individual TCR engineered T cell products in various phase 1 trials for various solid cancers
  • Extensive process development was carried out using primary T cells derived from multiple healthy donors and cancer patients to optimize each step in the manufacturing of TCR T cells for 3 clinical trials (IMA101, IMA201, and IMA202)
  • Manufacturing for 3 trials in progress and a 4th is in progress
Immunotherapy - Immunotherapy for solid tumours
12:25

T3 Pharma’s versatile bacterial cancer therapy

  • How to target bacteria to solid tumours
  • How to enable bacteria to fight solid tumours
  • Use of such bacteria in immunotherapy
Immunotherapy - Manufacture, logistics and supply chain
12:25

WORKSHOP: Logistics and supply chain management for cell therapy

  • Developing manufacturing that produces a high-quality product
  • Scalable to meet changing demands of cell therapies
  • Keeping reasonable cost of goods
  • Fully characterising cell therapy products
Immunotherapy - Immunotherapy for solid tumours
12:45

Targeting the integrin αvβ6 with CAR T-cells to treat multiple solid malignancies

  • The integrin αvβ6 is overexpressed in multiple solid cancers and is associated with poor prognosis
  • Development of CAR T-cells targeting αvβ6
  • Pre-clinical in vivo models to test CAR T-cell therapeutic approach
Lynsey Whilding, Research Associate, King's College London
Immunotherapy - Manufacture, logistics and supply chain
12:45

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

Networking lunch

Oncology – combination therapy

Chaired by Frédéric Triebel, Chief Scientific Officer, Chief Medical Officer, Prima BioMed

Immunotherapy - Combination therapy
14:35

Expanding immunotherapy by changing the tumour microenvironment

  • MedImmune has a portfolio of therapies aimed at expanding the patient population that will be responsive to immunotherapy Including:
  • Modulating adenosine by CD73 blockade
  • Cytokine expressing Oncolytic virus
Matthew Robinson, Associate Director, Oncology Research, MedImmune Cambridge
Immunotherapy - Combination therapy
14:55

Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab

  • Understand the rationale for combining an APC activator (LAG-3lg or “efti”) with an immune checkpoint inhibitor (anti-PD-1 pembrolizumab)
  • Pharmacodynamic effects of efti (6 or 30 mg s.c.) in patients
  • Highlighting in vitro and in vivo preclinical data along with emerging clinical data
Immunotherapy - Combination therapy
15:15

IgA as novel antibody format for lymphoma and neuroblastoma is enhanced by myeloid checkpoint inhibitors

  • IgA recruits neutrophils as effector cells for treatment of cancer
  • Preclinical evidence for mode of action of IgA
  • Adverse effect for neuroblastoma treatment is eliminated with IgA
  • Myeloid checkpoint block strongly enhances IgA effects
Immunotherapy - Combination therapy
15:35

Hexavalent TNFR-SF agonists for cancer Immunotherapy: HERA-CD40L, HERA-CD27L and beyond

  • Understand the structure function relation of the TNFR-SF/TNF-SF interaction and the subsequent design of the HERA-fusion proteins
  • In vitro and in vivo preclinical data illustrating the activity of HERA-based agonists to specifically activate distinct immune cell types involved in the anti-tumor immune reaction
  • Outlook on potential combinations with other IO-drugs

15:55 Networking Break

Oncology - neoantigens

Immunotherapy for non-oncology

Chaired by Agnete Frederiksen, President and Chief Scientific Officer, Vaccibody

Chaired by Ahuva Nissim, Professor, William Harvey Research Institute, Queen Mary University

Immunotherapy - Neoantigens
17:00

Driving high T-cell titers to neoantigens in tumours – harnessing immunogenic viral vectors with immune check point modulators

  • DNA damage may cause mutations in tumours that can generate new antigens, known as tumour-specific neo-antigens (TSNAs)
  • Accurate prediction of TSNAs is key to generate potent TSNA specific vaccine approaches
  • Viral vector based vaccine platforms have shown to induce hi-titer, polyfunctional and durable CD4+ and CD8+ T-cell responses in humans
  • The personalized vaccine is delivered in combination with immune checkpoint blockade, to keep TSNA-induced T-cells active in the immunosuppressive tumour microenvironment
Immunotherapy - Immunotherapy for non-oncology
17:00

Targeting combined treatments to arthritic joints by antibody-specific to damaged cartilage: a safer therapy platform for rheumatoid arthritis

  • There are 40% of patients with rheumatoid arthritis that do not respond to treatments
  • A major issue with systemic treatment due to side effects
  • We developed a platform that can address these unmet needs by:
    • Targeting treatments to the disease tissue
    • Utilize the efficacy of combined biologics which could otherwise lead to major advert effects if administered systemically
Immunotherapy - Neoantigens
17:20

ACE ImmunoID platform for the next generation of cancer immunotherapies and combination clinical trials

  • Current limitations with conventional next generation sequencing assays and Personalis’ solutions to overcome these challenges with its Accuracy and Content Enhanced technology
  • Key considerations for designing rapid, patient-centric processes for neoantigen-based cancer vaccine clinical trials and combination therapies
  • A case study demonstrating the platform’s applicability in identifying multidimensional biomarkers for cancer immunotherapy
Immunotherapy - Immunotherapy for non-oncology
17:20

The promises of low dose IL-2 in autoimmune diseases

  • There is a regulatory T cell (Treg) insufficiency in most autoimmune diseases
  • IL-2 is the main cytokine supporting survival and activation of Tregs, and also block the differentiation of IL-17 and Tfh cells
  • IL-2 has proved efficient in more than 30 experimental models of autoimmune or inflammatory diseases in mice
  • We report “universal” biological and clinical effects of IL-2 in patients with one of 14 different autoimmune diseases treated in the same clinical trial
Michelle Rosenzwajg, MCU-PH, Pierre et Marie Curie University and Medical School
Immunotherapy - Neoantigens
17:40

Development of a cost-effective personalized cancer neoantigen vaccines inducing a unique CD8-dominated T cell response

  • Potentiating vaccines by attracting, activating and delivering antigens to antigen presenting cells
  • Targeting results in a unique CD8-dominated T cell response.
  • DNA vaccine format allows a rapid, cost-effective and robust manufacturing process viable for manufacturing patient-specific vaccines on demand
  • A clinical study using targeted Vaccibody neoepitope DNA vaccines in multiple advanced cancer indications is ongoing
Immunotherapy - Immunotherapy for non-oncology
17:40

Proteomics crashes at the intersection of autoimmunity and cell biology

  • Review novel protein modifications that trigger autoimmune responses and pathology
  • Discuss proteins modifications that also alter cell biology and metabolism
  • Protein biomarkers as indicators of disease progression and therapeutic strategies
Immunotherapy - Neoantigens
18:00

Individualized therapeutic cancer vaccines – How to select for immunogenic neoantigens?

  • Selecting the right tumour specific antigens - the key for successful therapeutic T cell cancer vaccines
  • Bypassing prediction - identification of tumour specific T cell antigens by a functional readout
  • Vaccination with common tumour antigens - decoding the “Mutanome” presented on HLAs
Immunotherapy - Immunotherapy for non-oncology
18:00

Combinatorial therapeutic HIV-1 vaccines: Time for immune checkpoint inhibitors

  • Talk will focus on HIV-1 infected and treated patients who received therapeutic vaccination
  • Discuss the current work on how to improve therapeutic vaccination using immune checkpoint inhibitors

18:20 Poster presentation and networking drinks

last published: 15/Oct/18 13:05 GMT

 

There are two parts to the Festival of Biologics: the five world-class international conferences covering Antibodies, Immunotherapy, BioSimilars, Clinical Trials, and High Potency APIs; and an exhibition featuring the most exciting technology and solutions for pharma and biotech. There is a registration fee to attend the conferences. To visit the exhibition is free.


Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates